CONTROLING INTESTINAL COLONIZATION OF HIGH-RISK PATIENTS WITH EXTENDED- SPECTRUM BETALACTAMASE PRODUCING ENTEROBACTERIACEAE (ESBL-E) – A RANDOMIZED TRIAL (CLEAR)

Trial Profile

CONTROLING INTESTINAL COLONIZATION OF HIGH-RISK PATIENTS WITH EXTENDED- SPECTRUM BETALACTAMASE PRODUCING ENTEROBACTERIACEAE (ESBL-E) – A RANDOMIZED TRIAL (CLEAR)

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Fosfomycin tromethamine (Primary) ; Colistin; Gentamicin
  • Indications Bacterial infections
  • Focus Therapeutic Use
  • Acronyms CLEAR
  • Most Recent Events

    • 03 May 2017 Status changed from recruiting to discontinued.
    • 05 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.
    • 05 Feb 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Oct 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top